

## Special Issue

# Innovative Drug Delivery Strategies for Targeted Cancer Immunotherapy

### Message from the Guest Editor

Cancer immunotherapy, including checkpoint inhibitors, adoptive cell transfer, cancer vaccines, and cytokines, has emerged as a revolutionary approach to treating various malignancies by harnessing the body's immune system. Despite its promise, the clinical success of immunotherapy is often limited by therapeutic agents' delivery efficiency and specificity. Innovative drug delivery strategies are essential to overcome these barriers, enhancing the delivery and uptake of immunotherapeutic agents and reducing systemic toxicity. By incorporating cutting-edge technologies, researchers are developing various delivery systems (e.g., liposomes, polymeric carriers, inorganic nanoparticles, extracellular vesicles, cell membrane-coated nanoparticles) that can selectively target tumor and immune cells, providing controlled release of therapeutics to modulate the immune response. This Special Issue focuses on the latest advancements in drug delivery systems engineered to enhance the efficacy and specificity of cancer immunotherapies.

---

### Guest Editor

Dr. Jingjing Sun

Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68105, USA

---

### Deadline for manuscript submissions

30 September 2026



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/210060](https://mdpi.com/si/210060)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).